Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.31 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TLR4 | O00206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15142824 | 1.00 | PYGB (0.40) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL20045971 | 1.00 | PYGB (0.40) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL23315803 | 0.90 | PYGB (0.48) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL19757478 | 0.90 | PYGB (0.48) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL23651957 | 0.90 | PYGB (0.48) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL19757480 | 0.90 | PYGB (0.48) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL20045969 | 0.81 | PYGB (0.37) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL15142817 | 0.81 | PYGB (0.37) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL20045990 | 0.81 | PYGB (0.37) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL16359157 | 0.80 | ALDH1A1 (0.45) | PYGBGAALGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGB4 | PYGB 2053/4885GAA 1685/4885KDM4E 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.